Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 — Myeloma Research News

Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated Phase 1 data is expected to show. An earlier analsyis showed that, among patients receiving doses of 150 million cells or higher, 94 percent responded to the treatment, including 56…

via Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 — Myeloma Research News

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s